HP-560

N/A

Report date: 2025/03/31 10:53:15
NME

Base Information

Drug NameHP-560
Drug Alias NameHP-560HP560
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsPrimary MyelofibrosisHematologic NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHinova Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHinova Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisHematologic NeoplasmsTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A